WO2014074331A1 - Composition de revêtement antimicrobienne de surface à faible adhérence et procédé d'application - Google Patents

Composition de revêtement antimicrobienne de surface à faible adhérence et procédé d'application Download PDF

Info

Publication number
WO2014074331A1
WO2014074331A1 PCT/US2013/066929 US2013066929W WO2014074331A1 WO 2014074331 A1 WO2014074331 A1 WO 2014074331A1 US 2013066929 W US2013066929 W US 2013066929W WO 2014074331 A1 WO2014074331 A1 WO 2014074331A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating composition
antimicrobial
microorganisms
composition
coating
Prior art date
Application number
PCT/US2013/066929
Other languages
English (en)
Inventor
Afif Mahmoud GHANNOUM
Brian Vincent SOKOL
Original Assignee
ARMS Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/734,363 external-priority patent/US20130123308A1/en
Application filed by ARMS Pharmaceutical LLC filed Critical ARMS Pharmaceutical LLC
Publication of WO2014074331A1 publication Critical patent/WO2014074331A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40—Additives
    • C09D7/60—Additives non-macromolecular
    • C09D7/63—Additives non-macromolecular organic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/17—Amines; Quaternary ammonium compounds

Definitions

  • This disclosure relates to coating compositions and methods for treating surfaces to kill or neutralize microorganisms.
  • Hand-washing or surface sanitization typically has a very short-lived duration and many microorganisms will quickly begin regrowth or new microorganisms will become deposited on the surface.
  • Physical devices such as masks are uncomfortable, zinc, vitamin C, and herbal remedies have unproven results, and surface sanitizers and solutions for killing germs that have already contacted the body are often ineffective for prevention of infection since they are intermittent, transitory options that do not provide sustained antimicrobial duration.
  • compositions have been developed for killing germs on household surfaces, healthcare facility surfaces, workplace or office surfaces, and other various surfaces that from time to time become contaminated.
  • these compositions typically contain highly volatile organic compounds, and although they almost immediately kill
  • microorganisms they quickly evaporate and/or are washed or wiped away and do not continue to inhibit microorganism growth for more than a few minutes. In addition, it is unlikely that a quick application of such compositions will kill all the microorganisms present on the surface. Thus, the remaining microorganisms will inevitably begin regrowing in a short time.
  • compositions have also been developed that mask or destroy odors or act to kill mold or other microorganisms that cause a deterioration in a visual aspect of a surface.
  • improvements in a long-lasting, powerful and generally non-toxic solution for such uses is desirable.
  • a method for trapping and neutralizing or killing microorganisms on a surface includes: applying a coating composition that comprises an antimicrobial agent onto an inanimate surface; in the coating, killing or neutralizing microorganisms encountered on the surface and encountered from the environment after the applying step is performed; forming a coating layer on the inanimate surface.
  • the composition comprises a humectant and an antimicrobial, the antimicrobial including a monoquaternary ammonium compound or pharmaceutically acceptable salt thereof.
  • the coating layer has antimicrobial cidal or static activity for at least about one hour.
  • an antimicrobial coating composition for a surface treatment comprising: about 0.07% ⁇ H ⁇ about 10% and 0.0005% ⁇ A, wherein all percentages are by weight of the total composition, wherein H is a humectant and A is an antimicrobial agent.
  • the antimicrobial comprises a monoquaternary ammonium compound or a pharmaceutically acceptable salt thereof; and the coating layer has an antimicrobial cidal or static activity for at least about one hour.
  • the coating composition retains about 35% or more of cidal or static activity after washing the surface with water.
  • a method for trapping and neutralizing or killing microorganisms on a surface includes: applying a coating composition that comprises an antimicrobial agent onto an inanimate surface; in the coating, killing or neutralizing microorganisms encountered on the surface and encountered from the environment after the applying step is performed; forming a coating layer on the inanimate surface.
  • the composition comprises a
  • the coating layer has an antimicrobial cidal or static activity for at least about one hour.
  • mammal means a human or animal commonly defined as a mammal.
  • block or blocking means blocking passage by trapping.
  • Figure 1A is an illustrated flow chart of a treated and untreated inanimate surface and the results of an encounter with microorganisms.
  • Figure IB is a depiction of a proposed mechanism of antimicrobial activity in an embodiment of the coating composition.
  • Figure 2 is a schematic showing the formation of a barrier on a mucosal surface, as described in Example 2.
  • Figure 3 is a schema showing the method of evaluation of microbial growth in the upper and lower chambers of an EHOM assay, as described in Examples 27-28.
  • Figure 4 show photographs of agar media plates showing microbial growth in the upper and lower chambers of an EHOM assay, as described in Examples 27-28.
  • FIG. 1 shows photographs of magnified cross-sections of the coating-composition- treated and untreated engineered human oral mucosa (EHOM) of Examples 31-32.
  • Figure 6 shows photographs of microbial growth on untreated EHOM or EHOM treated with an example coating composition, followed by infection with C. albicans, as described in Examples 33-40.
  • Figure 7 shows photographs of microbial growth on untreated EHOM or EHOM treated with formulations followed by infection with S. mutans, as described in Examples 33- 40.
  • Figure 8 shows photographs of microbial growth from "flow-through" media
  • Figure 9 presents graphs showing LDH release by EHOM treated with saline (control) or example coating compositions, followed by infection with (A) C. albicans or (B) S.
  • Figure 10 is a graph showing post-antimicrobial effect of coating compositions against bacteria and fungi, as described in Examples 63-69.
  • Figure 11 shows scanning electron micrographs of S. sanguis, C. albicans, and S. mutans, untreated or treated with coating composition, as described in Examples 71-76.
  • Figure 12 presents graphs depicting activity of an example coating composition against biofilms formed by bacteria and fungi, as described in Examples 77-79.
  • Figure 13 is a graph showing activity of an example coating composition on microbial biofilms after a 1-min exposure, as described in Examples 80-81.
  • Figure 14 presents fluorescent microscopy photographs showing the effect of an example coating composition on cytopathic effects (CPE) of influenza (Hl l)-infected
  • MDCK cells as described in Examples 85-86.
  • Figure 15 presents fluorescent microscopy photographs showing the effect of an example coating composition on against H1 1 virus, as described in Examples 85-86.
  • Figure 16 is a graph showing levels of influenza virus in infected coating composition treated and -untreated cells, as determined by quantitative PCR, as described in Examples 87- 88.
  • Figure 17 is a graph showing direct antiviral activity of example coating compositions prepared with or without preservatives and antimicrobial agent (CPC) against influenza virus, determined using quantitative PCR, as described in Examples 89-91.
  • CPC antimicrobial agent
  • Figure 18 shows the activity of an example coating composition against H1N1 virus over a 6 hour time period.
  • Panel (A) is a graph showing a percent inhibition in viral growth compared to an untreated control.
  • Panels (B) and (C) are micrographs of (B) untreated and (C) coating composition treated cells.
  • Figure 19 is a graph showing the activity of formulations against HIV, as described in Examples 94-96.
  • Figure 20 is a Western blot showing activity of Example 8 against Epstein-Barr Virus (EBV), as described in Example 97.
  • EBV Epstein-Barr Virus
  • Figure 21 are photographs demonstrating the ability of an example coating composition to coat the oral mucosal surface.
  • Figure 22 are photographs showing time-lapse microscopy of bacterial growth after a 1 minute exposure to an example coating composition, as described in Examples 162-163. Images represent bacterial growth after 20 min, 120 min, or 360 min post-exposure.
  • Figure 23 is a graph showing the effect of a single dose of an example coating composition on oral microbial burden of a healthy individual, as described in Example 164- 166.
  • A - Microbial load in CFUs
  • B reduction in microbial load (%) compared to baseline.
  • Figure 24 is a graph showing the effect of an example coating composition on levels of oral microbes over a 5-day period in three healthy adults, as described in Examples 167- 169.
  • Figure 25 is a graph showing the effect of an example coating composition on microbial burden of the oral cavity after 5 -day usage in 31 healthy subjects, as described in Examples 170-198.
  • Figure 26 is a graph showing the microbial load in oral samples obtained from three representative study participants, as described in Examples 170-198.
  • Figure 27 shows is a schema describing the in vitro filter insert-based model to evaluate penetration of microbes across the barrier formed by example coating compositions, as described in Examples 199-205.
  • Figure 28 is a set of photographs showing growth of MRSA biofilms on the surface of silicone elastomer discs treated with PBS (control, A, C, E) and Example 7 coating composition (B, D, F), as described in Examples 219-224.
  • Figure 29 is a set of photographs showing cell monolayers treated with an
  • Example 252 for varying time periods (a), (b), and (c), and a control Example 253 (d).
  • Figure 30 is a set of immunofluorescence photographs showing cell monolayers treated with an embodiment of the coating composition, Example 252, for varying time periods (a), (b), and (c), and a control Example 253 (d).
  • Figure 31 is a graph showing a test composition and a comparison after a water-wash that corresponds to Example 255.
  • Figure 32 shows photographs depicting a gum-containing embodiment in comparison to a no-gum embodiment demonstrating tackiness, viscosity, and thickness differences.
  • Figure 33 shows photographs depicting a gum-containing embodiment in comparison to a no-gum embodiment demonstrating viscosity, thickness, and surface coverage differences.
  • Figure 34 shows photographs depicting a gum-containing embodiment in comparison to a no-gum embodiment demonstrating a difference in residue film.
  • This application discloses a stable coating composition for treating/cleaning surfaces that provides a long-term, sustained microbial static or cidal activity that inhibits or destroys harmful microbial growth that also has a barrier-forming property.
  • the composition is also non-toxic for human consumption and safe for human mucosal cells or wounds.
  • the coating composition presented herein displays low tack (stickiness), has high surface area coverage, low viscosity, low layer thickness, and in a coating layer is transparent and substantially free of visible residue. As such, it provides advantages over certain embodiments disclosed in prior U.S. application 13/734,363. It was also discovered that the composition is also superior in antimicrobial properties after a water rinse in comparison to a typical commercial cleaner.
  • the coating composition is not required to have any carbohydrate gum and may also have a low amount of humectant.
  • the method and composition incorporates an antimicrobial agent that can inhibit microorganisms, including bacteria, fungi, and viruses, known to cause infections.
  • the method provides a coating layer on a surface by forming a coating layer or film over it and an antimicrobial agent is included that can kill or inhibit microorganisms (bacteria, fungi and viruses).
  • the coating composition is also effective against microorganisms that cause odor and detraction of the visual aesthetic appearance of surfaces.
  • the composition in an embodiment, is safe and non-toxic for such consumption.
  • the surface treatment composition would be expected to be safe even if, for example, a child puts their mouth directly on the treated surface and ingests a portion of the composition.
  • the composition is non-toxic to humans, wherein at least a portion of the composition may be ingested and is safe and non-toxic for human
  • the term "safe,” in this context, includes not damaging to normal skin or mucosal cells or wounds, or causing a reduction in wound healing rate.
  • at least a portion of the composition may be ingested and is safe for human consumption.
  • the composition is free of harmful side effects on humans.
  • a utensil or other item that contacts food may be coated with the coating composition and may impart some of the composition to food surfaces that then contact mucosa of a human and become ingested.
  • the coating composition is active to inhibit microbial growth through static or cidal activity for an extended period of time.
  • the mechanism of action of the coating composition disclosed herein is based on a synergistic dual-action mechanism, in which germs are trapped in the formed coating layer, and subsequently killed by the antimicrobial active ingredient.
  • the coating composition is not hydrophilic, which, without being bound by theory, is theorized to enhance its sustained effectiveness. For certain applications the composition may be hydrophobic.
  • the coating composition exhibits low tackiness or stickiness.
  • the coating layer may have a draw depth of 0.5 inches or less, such as 0.01 inches to 0.4 inches, or 0.1 inches to 0.03 inches, when applied in a 0.25 mL dosage on a 1 inch diameter area of a paper-stock card, before the coating composition separates entirely from a second paper-stock card set against the coating layer.
  • the coating composition produces a thin layer coating.
  • the coating have an average thickness of from about 50 nanometers to about 0.2 mm, such as about 100 nm to about 900 nm, or about 0.01 mm to about 0.1 mm, or about 0.08 to about 0.15 mm.
  • the coating composition exhibits a substantially streak free appearance or the coating layer is transparent and does not show a visible residue.
  • the properties of the coating composition and its effectiveness to prevent a wide variety of communicable diseases were assessed using at least ten different approaches based on: (1) an in vitro anti-microbial susceptibility testing; (2) an in vitro time kill assay; (3) an in vitro biofilm model; (4) an in vitro filter insert-based model, (5) an in vz ' vo-like engineered human oral mucosa (EHOM) model; (6) electron microscopy evaluation; (7) hydrophobicity assay; (8) physico-chemical compatibility assays; (9) cell culture-based model using monolayer of human cell lines; (10) human clinical trials, and (1 1) a steel surface test with a water rinse.
  • EHOM in vitro filter insert-based model, (5) an in vz ' vo-like engineered human oral mucosa
  • the method and composition described herein may be particularly useful when a human, or more generally, a mammal, has a disrupted skin or mucosa or has a condition resulting in an immunocompromised state or is otherwise at a greater risk for infection.
  • a disruption may be caused by a wound, scratch, or other opening in the skin or mucosa.
  • the skin and the mucosa of the oral cavity and gastrointestinal (GI) tract serve as an important mechanical barrier that helps to prevent a local or systemic invasion of various microbes and the absorption of microbial products that are normally present in the oral cavity and the lumen of the gut.
  • GI gastrointestinal
  • a coating composition that traps and kills harmful microorganisms and that does not interfere with healing of a disrupted skin or mucosa is a unique and unexpected solution to the susceptibility of the problems of those with disrupted skin or mucosa, particularly those that also have immunodeficiency.
  • a coating composition may be applied in a method for preventing or inhibiting the transfer of microorganisms from the surrounding environment (including from surfaces and airborne particulates that later become deposited on a treated surface) to a mammal.
  • prevention it is not meant that no infection from microorganisms is possible, but that the risk of infection from microorganisms encountered at the time of application and/or subsequent to application of the coating composition is reduced.
  • the coating composition is applied in an effective amount to an inanimate surface and provides a barrier layer on the surface that traps microorganisms, such as by inhibiting microorganisms from penetrating to the other side of the barrier.
  • An antimicrobial is provided that kills or deactivates (neutralizes) the microorganism's harmful activity.
  • the combined barrier and antimicrobial synergistically act to trap, neutralize, and/or kill microorganisms on the inanimate surface or microorganisms that subsequently come into contact with an exposed (top) surface of the barrier, thereby providing a long-lasting antimicrobial that is significantly more powerful than just an antimicrobial alone.
  • the coating composition is effective to trap and kill or neutralize microorganisms already present on the treated surface and/or to kill or neutralize microorganisms that may be deposited on top of the coating, i.e., the exposed surface of the coating, after the application of the coating composition is performed.
  • the coating composition is active for at least about one hour after application.
  • This dual action composition and method is applicable to various surfaces found in a variety of places, including for example, homes, schools, churches, restaurants, daycares, workplaces, vehicles and medical buildings, such as, for example, ceramic, glass, wood, (including, for example, varnished, stained, or waxed wood), linoleum, CORIAN (a composition of acrylic polymer and aluminum trihydrate), Formica, porcelain, metal (including, for example, stainless steel, steel, iron, wrought iron, copper, brass, bronze, silver, gold, platinum, aluminum, and alloys of such metals), ceramic, painted surfaces, carbon fiber, textile materials (including, for example, wool, silk, cotton, hemp, sisal, velvet, aramid, acrylic, olefins, nylon, rayon, and spandex), concrete, stone (including, for example, granite, marble, soapstone, limestone, Jerusalem stone, quartz, travertine, and slate), plastic, tile, carpet, leather, laminate material, and rubber.
  • ceramic glass
  • wood including, for example, varnished, stained
  • Types of inanimate surfaces include, for example, countertop, table top, flooring, fixtures, furniture, toilet bowl, toilet seat, toilet flush knob, doorknob, faucet, bathtub, shower, hot tub, sauna, sink, clothing, food preparation equipment, playground equipment, toys, shoes, shoe inserts, sporting and fitness equipment, appliance housings, airplane interiors, military vehicle interiors, theater seating, surfaces in healthcare facilities, surfaces in high-traffic public spaces, surfaces in lobbies, surfaces in hotels, surfaces in cruise ships, surfaces in schools, surfaces in dormitories, surfaces in public transportation vehicles, surfaces in adult and child care facilities, surfaces in commercial kitchens, surfaces in manufacturing facilities, surfaces in restaurants, electronic input devices, dishware, and cutlery.
  • Figure 1A is an illustrated flow chart of microbes encountering an untreated inanimate surface (left side) and an inanimate surface with the coating composition administered on it resulting in a formed barrier coating layer (right side) that shows a primary efficacy of the coating composition on an inanimate surface.
  • the barrier coating layer prevents microorganisms from binding to the surface, colonizing and forming a biofilm. Biofilms are known to be difficult to destroy.
  • the coating composition thus presents a surprisingly effective solution to providing a sanitized surface in comparison to cleaners that only focus on killing microorganisms that are only already on the surface.
  • the coating composition prevents biofilms from forming in the first place and also has prolonged activity to destroy already formed biofilms. While the low tack embodiment of the coating composition may not be as robust at preventing passage of microorganisms as other embodiments with more humectant and carbohydrate gum, it was found to be effective in killing or neutralizing the microorganisms and was shown to have potent activity against MRSA.
  • the coating composition traps and/or kills or neutralizes all harmful microorganisms contacting the coating composition.
  • the barrier coating substantially traps and/or kills or neutralizes enough harmful microorganisms that contact the coating composition to inhibit or even stop them from causing an infectious disease.
  • In vitro testing shows that in viruses exposed to embodiments of the coating composition, growth may be inhibited for about two or more days (such as influenza), up to about nine days, (such as HIV), after which the viral count is still below the MIC for extended periods, such as about two or three additional days. Inhibitory activity against influenza virus was observed for up to 48 hours.
  • the coating composition may be transferred to the mammal and encounter a disrupted skin or a mucosal surface. Traces of active microorganisms may be present on the transferred coating composition or may be picked up from elsewhere and come into contact with the transferred coating composition. In this situation, without being bound to theory, certain embodiments of the still-active coating composition are expected to have additional antimicrobial preventative activity on the disrupted skin or mucosal site. In an embodiment that illustrates a proposed mechanism of the composition in such a case, shown in Figure IB, the composition provides anti-viral activity. When a virus comes into contact with a cell, it will bind to receptors on the host cell.
  • a protective coating is on the surface of the host cell.
  • the coating may protect the cell and any receptors on the cell, thereby preventing the virus particle from binding to the cell receptors. Thus, infection and lysis is also prevented.
  • the disrupted skin or mucosal surface, or a mucosal surface is also protected from bacteria or fungi.
  • the coating composition retains the barrier coating for a long duration, such as a duration of about 2 hours or more, a duration of about 6 hours or more, a duration of about 16 hours or more, a duration of about 16 hours to about 24 hours, or a duration of about 24 hours or more, thereby protecting host cells and preventing infection.
  • the cidal or static antimicrobial activity is also retained for a long duration, such as about 2 hours or more, about 6 hours or more, about 16 hours or more, about 24 hours or more, or about 48 hours or more, thereby killing microorganisms before they can be transferred to mammals and even if transferred to mammals continuing to protect host cells and preventing infection. These durations are applicable for viruses, bacteria, and fungi.
  • the coating composition is applied on an item or apparatus surface prior to the item or apparatus surface encountering a contaminated environment and prior to the apparatus encountering a mucosa of a mammal.
  • the coating composition provides a barrier coating on the item or apparatus surface that traps and kills the
  • Harmful microorganisms are those known to cause infectious disease such as, for example, the treatment and prevention of infectious diseases, such as communicable diseases caused by microorganisms, such as Candida species (e.g. C. albicans, C. glabrata, C. krusei, C.
  • Staphylococcus species including methicillin-resistant S. aureus, MRSA
  • Streptococcus species e.g. S. sanguis, S. oralis, S. mitis, S. salivarius, S. gordonii, S.
  • Fusobacterium nucleatum, and other microorganisms such as microorganisms that cause upper respiratory infections, and common cold (rhinovirus) and influenza viruses and Pneumonia, P. gingivalis, Y. enterocolitica, Acinetobacter bumanii, Aggregatibacter actinomycetemcomitans, microorganisms that cause odor, microorganisms that can detract from visual appeal of surfaces, Clostridium difficile, Bordetella pertussis, Burkholderia, Aspergillus fumigatus, Penicillium spp, Cladosporium, Klebsiella pneumoniae, Salmonella choleraesuis, Escherichia coli (0157:H7), Trichophyton mentagrophytes, Rhinovirus Type 39, Respiratory Syncytial Virus, Poliovirus Type 1, Rotavirus Wa, Influenza A Virus, Herpes Simplex Virus Types 1 & 2, Hepatitis A Virus, Influenza B
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for prevention of sexually transmitted diseases such as, for example, infections caused by human immunodeficiency virus (HIV), Herpes simplex, or human papilloma virus (HPV).
  • sexually transmitted diseases such as, for example, infections caused by human immunodeficiency virus (HIV), Herpes simplex, or human papilloma virus (HPV).
  • the coating composition has shown effectiveness against microorganisms with a diameter of, for example, about 30 nm or greater, such as about 100 nm (HIV, spherical), about 100 to about 300 nm (influenza, spherical and elongated forms), about 120 nm to about 260 nm (EBV spherical/disk forms), and about 30 nm (rhinovirus, spherical).
  • the coating composition should also be effective against other microorganisms with diameters of about 30 nm, or greater than about 30 nm.
  • the coating composition has even shown powerful and surprising activity inhibiting biofilms, which can be very difficult to eradicate.
  • the method comprises administering the coating composition to a formed biofilm on a surface or inhibiting microorganisms encountered by the coating from forming a biofilm.
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for prevention and/or treatment of odors emanating from microorganisms present on or growing on any of the surfaces mentioned above.
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for the prevention and/or treatment of odors from microorganisms deposited on kitchen or bathroom surfaces, or any other surfaces mentioned herein.
  • the coating composition may be used to prevent odor from bacteria deposited during food preparation, from spills of food or drink or bodily fluids on carpet or vehicle interiors, or any number of other occurrences where odor causing microorganisms are deposited or grow on surfaces.
  • Odor causing microorganisms include, for example, bacteria and fungi. Specific examples that may be mentioned, include, Centipeda periodontii, Eikenella corrodens, Enter obacteriaceae, Fusobacterium nucleatum subsp. nucleatum, Fusobacterium nucleatum subsp. polymorphum, Fusobacterium nucleatum subsp. vincentii, Fusobacterium
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for treatment and prevention of detraction of the visual aesthetic appearance of surfaces. Such detraction of the visual aesthetic appearance of a surface may be caused by microorganisms that produce a visible growth on a surface and/or discoloration of a surface.
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for prevention and/or treatment of staining of tile grout by mold, or prevention and/or treatment of basement floor or wall surfaces.
  • Microorganisms that cause detraction of the visual aesthetic appearance of surfaces include, for example, fungi. Microorganisms that cause detraction of the visual aesthetic appearance of surfaces may also be considered harmful microorganisms for purposes of this application.
  • the microorganisms may be air-borne microorganisms.
  • the microorganisms are those that cause communicable diseases.
  • the microorganisms do not include those that cause allergic reactions or dental problems, such as, for example, cavities (caries), gingivitis, or seasonal allergies.
  • the method of prevention does not solely or additionally prevent dental problems or allergic reactions, such as, for example, cavities (caries), gingivitis, or seasonal allergies.
  • microorganisms such as fungi that may generally be classified as allergens, other allergens, and airborne irritants to the mucosa, are trapepd by the barrier coating and the method. It may be especially useful to treat surfaces with the coating composition if an allergic mammal is expected to be in a location known or expected to produce a high number of allergens or airborne irritants, such as an outdoor environment.
  • compositions disclosed herein may be especially applicable for treating surfaces that immunocompromised persons will encounter.
  • coating composition may be useful for prevention and/or treatment of infections by microorganisms that commonly infect wounds on the mucosa or skin.
  • the coating composition and method of treatment and prevention described herein may be useful, for example, for prevention and/or treatment of infections from items that may be contaminated in activity related treatments, such as, for example, ventilator use (which would include medical devices related to the ventilator and contacting the patient).
  • activity related treatments such as, for example, ventilator use (which would include medical devices related to the ventilator and contacting the patient).
  • a contaminated item treatment and prevention of fungal infections through applications to the body, and or items or surfaces coming into contact with the body, such as shoes, may also be mentioned.
  • the contaminated item may be, for example, a food, a drink, utensils, drink containers and accessories, an item for use by children, a medical apparatus, or a dental apparatus.
  • the interior surface of an apparatus protecting the feet is treated with an effective amount of the coating composition to destroy, inhibit or prevent odor from fungal growth.
  • the shoe may be treated proactively by administering the composition prior to a person wearing the shoe.
  • the shoe may be treated prior to a person exercising or participating in an activity where their feet or shoes may become wet.
  • the shoe is treated when a person knows that they have a fungal condition on their foot, such as athelete's foot (tinea pedis).
  • the shoe may be treated if it is producing a foul odor.
  • the coating composition traps and kills or prevents fungal or other microbial growth, thereby reducing the risk of infection on the human's foot and masking and/or neutralizing the foul odor produced by the microorganisms.
  • the surface of a medical device is treated with the coating composition prior to contacting the human body.
  • the coating composition provides a coating on the medical device surface that traps and kills microorganisms.
  • Medical devices include, for example, instruments, apparatuses, and other articles of manufacture that are intended to contact or come in close proximity with the human body, such as human tissue, bloodstream, mucosa, open wounds, and internal cavities.
  • medical devices include ventilators, trachea devices, catheters, central venous catheters, urinary catheters, peritoneal dialysis catheters, contact lenses, total joint replacement prostheses, endotracheal tubes, voice prostheses, penile prostheses, testicular prostheses, prostatic stents, artificial urinary sphincters, breast prostheses, vascular graft, orthopedic devices, prosthetic heart valves, scalpels, scopes, implanted replacement devices, In an embodiment, medical devices also include dental devices.
  • the medical device is treated with the coating composition prior to encountering the human body, such as up to about 12 hours prior to encountering the human body, for example, about 5 minutes to about 8 hours, about 12 minutes to about 6 hours, or about 1 hour to about 10 hours, prior to encountering the human body.
  • the medical device is treated with the coating composition in a spray formulation by spraying the medical device until a moist coating appears on the surface.
  • the medical device is treated by dipping the medical device in the coating composition and withdrawing it from the composition, which results in a residual coating layer on the medical device.
  • the medical device is a catheter or similar device that is inserted into a mammal body canal, such as the throat, the anal, vaginal, or urethral canals.
  • a mammal body canal such as the throat, the anal, vaginal, or urethral canals.
  • the coating is applied to the medical device prior to encountering the body canal and, as it is inserted, also helps to lubricate the body canal and provide antimicrobial activity along the canal.
  • the medical device is an implanted device, such as a replacement hip part.
  • the coating is applied to the medical device prior to encountering the body canal and provides a long-lasting and powerful antimicrobial coating, thereby guarding against microorganisms that were on the medical device prior to the treatment and also any microorganisms that encounter the medical device after the treatment.
  • the medical device that contacts more than one location on the body such as a catheter, scope or a device used in surgery. Treating such a medical device prior to the first contact with the body may reduce the risk of transferring infectious microorganisms from one area of the body to another.
  • the method of treating a surface with the coating composition includes identifying a contaminated surface, wherein the contaminated surface is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms.
  • the step of applying the coating composition occurs prior to or during a mammal that is not contaminated encountering the contaminated surface.
  • the application of the coating composition occurs in response to the identification of the surface as being contaminated or in response to an observation of a contamination event.
  • the coating composition may be applied to a surface where a contamination event has occurred, such as when a person has sneezed, coughed, or vomited, or more generally where bodily fluids or matter have been deposited.
  • the method of treating a surface with the coating composition includes identifying a contaminated surface, wherein the contaminated surface is known or expected to be contaminated with odor causing viral, fungal, or bacterial microorganisms.
  • the step of applying the coating composition occurs prior to or during an odor emanating from the contaminated surface.
  • the coating composition may be applied to a surface where food is handled or bodily fluids are deposited, or any of the surfaces listed herein.
  • a method includes preventing or decreasing odor produced by microorganisms, by performing the steps of applying a coating composition that comprises an antimicrobial onto an inanimate surface.
  • the coating composition then quickly forms a coating layer on the inanimate surface that is active to trap, and kill or neutralize
  • the method includes identifying an area of the inanimate surface that is a source of the odor, and applying the coating composition to the area.
  • the method of treating a surface with the coating composition includes identifying a contaminated surface, wherein the contaminated surface is known or expected to be contaminated with viral, fungal, or bacterial microorganisms that cause detraction of the visual aesthetic appearance of surfaces.
  • the step of applying the coating composition occurs prior to, during, or after a detraction of the visual aesthetic appearance of the contaminated surface occurs.
  • the coating composition may be applied to bathroom tile grout that show visual signs of mold growth or are expected to come in contact with mold, or on other surfaces mentioned herein that show visual signs of mold growth or are expected to come in contact with mold.
  • the method includes preventing or treating a detraction of a visual appearance of a surface, where the detraction is caused by microorganisms that produce a visible growth on the surface or discoloration of the surface.
  • the treatment or prevention is facilitated by the steps of applying a coating composition that comprises an antimicrobial onto the surface; forming a coating layer on the surface that is active to trap, and kill or neutralize microorganisms encountered by the coating layer for a duration of at least about one hour, thereby preventing or decreasing the visible growth or discoloration on the surface.
  • the microorganisms that encounter the coating layer may be those that were already present on the surface that was treated or those that are disposed on the exposed top surface of the coating layer after it is applied.
  • the method includes identifying an area of the surface that has a visible microbial growth or discoloration, and applying the coating composition to the area.
  • the method of treating a surface with the coating composition includes treating the surface with the coating composition proactively, regardless of whether the surface is known or expected to be contaminated with viral, fungal, or bacterial microorganisms.
  • the administered coating traps and kills microorganisms that encounter the coating after the treating step.
  • the coating is effective to kill microorganisms encountered for a long duration after the treatment step, thereby facilitating its effectiveness as a proactive treatment, which stands in contrast to prior art antimicrobial compositions that are not effective for proactive treatment, partly due to their ineffectiveness for long time-periods.
  • the method of treating a surface with the coating composition includes treating a food surface with the coating composition.
  • the method of treating a food surface with the coating composition includes identifying a possibly contaminated food surface or a contamination event occurring in the vicinity of the food surface, wherein the surface is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms or be exposed to the same.
  • the food surface may be selected from produce, such as fruits and vegetables, including for example, salad vegetables, lettuce, cabbage, onions, spinach, broccoli,carrots, brussel sprouts, potatoes, nuts, carrots, apples, oranges, bananas, berries.
  • the food surface may include meat, such as, for example, raw meat including, for example, beef, pork, lamb, chicken, and turkey.
  • the food surface may also include processed meats, such as bologna, salami, pepperoni, and frankfurters.
  • the coating composition may be applied to a food surface that is deemed to have a heightened risk of e. coli, salmonella, botulism, or listeria.
  • the heightened risk may be based on knowledge of prior infections of a certain type of food surface or known contaminations of food surfaces in a common locality.
  • the heightened risk may be based on a known or expected exposure of the food surface to a contaminant.
  • the food surface is treated in response to a contamination event, such as a person sneezing or coughing in the vicinity of the food surface. For example in the same room, vehicle, or within about 10 yards of the food surface.
  • a contamination event such as a person sneezing or coughing in the vicinity of the food surface. For example in the same room, vehicle, or within about 10 yards of the food surface.
  • the food surface may be treated proactively to prevent contamination of microorganisms that may contact the food surface after the treatment, such as for up to 24 hours after treatment, or between about 12 minutes to about 6 hours, or between about 1 hour to about 8 hours post-treatment.
  • produce that is available to be touched by numerous customers such as in a supermarket or salad bar, may be treated proactively with the coating composition in the anticipation of guarding against a contamination event or contaminated environment.
  • the coating composition is rinsed off prior to consumption.
  • the coating composition is safe for human consumption in the therapeutically effective amount and is not rinsed off the food surface prior to consumption.
  • the proper amount to apply to a surface is an amount that is enough to coat the targeted surface with enough of the coating composition to form a coating layer, for example, this may be determined by whether the surface appears wet or misted.
  • the effective amount may be expressed in terms of a volume per square cm, such as, for example, from about 0.5 to about 50 ⁇ /cm 2 , such as, about 5 to about 40 ⁇ /cm 2 , or about 10 to about 25 ⁇ /cm 2 ; or for example, about 0.625 to about 10 ⁇ /cm 2 , such as, about 2.5 to about 5 ⁇ /cm 2 .
  • the coating composition may provide more surface coverage per volume.
  • the coating layer may covers an area of approximately 50,000 mm 2 to about 1,000 mm 2 per microliter of composition, such as, for example, about 30,000 mm 2 to about 10,000 mm 2 , or about 5,000 mm 2 to about 2,000 mm 2 .
  • the coating forming composition in a continued application method of prevention and/or treatment, may be administered to a surface in a series of doses, such as, for example, about every 1 to 2 days, about every 2 to 4 days, or about every 1 to 2 weeks.
  • This method of prevention and/or treatment can be continued, for example, for 6 to 12 months or for several years.
  • This continued application method may be preferred during flu season or outbreaks of particular illnesses, or simply as part of a routine cleaning schedule.
  • methods of applying the coating composition include, for example, rubbing, mopping, wiping, or spraying the composition onto the surface.
  • the coating composition may be applied to the surface through many different delivery systems, including, for example: dilutable liquids, gels, lubricants, compositions sprayable by a mechanical action pump, aerosolized spray compositions, or infusion or layering of the coating composition into or onto products, such as disposable wipes.
  • the coating composition is sprayed onto a surface in an amount sufficient to coat the surface with a mist or thin layer of liquid.
  • One or more sprays may be required to coat the surface depending on the size of the surface. Areas that are considered especially contaminated with microorganisms may be treated more heavily than others.
  • Wiping or rubbing is not required in this embodiment.
  • a mechanical pump spray or an aerosolized spray device may be used.
  • the coating composition may be mixed with common propellant agents, such as CO 2 , nitrogen, and hydrocarbons.
  • a bag-on-valve embodiment may also be used; however, the composition is stable enough so as not to require a separation of the propellant agent and the composition components.
  • the coating composition is applied by wiping the composition onto the surface from a material that includes the coating composition.
  • a material that includes the coating composition For example, a cloth, a mop, a scrubbing brush, a toilet cleaning brush, or a paper towel, may be at least partially saturated with the coating composition. The composition may then be wiped or mopped or otherwise applied to the surface from the material.
  • the composition can be applied by spraying and subsequent wiping of the sprayed composition.
  • a disposable wipe is pre -treated with the coating composition.
  • the wipe can simply be removed from a container and then be rubbed on the desired surface to apply the coating composition to the surface.
  • the wipe can then be disposed of.
  • Common materials for disposable wipes include, for example, wood pulp, viscose, polyester, cotton, and combinations of these.
  • the wipe can be soaked in and then removed from the coating composition for the pre-treatment step.
  • the wipe should be at least partially saturated with the coating composition.
  • the surface should be wetted with the wipe to provide an effective barrier coating. After wiping the surface, a coating composition is deposited that forms a thin film barrier coating on the surface and is active to inhibit microorganisms that contact the barrier coating from escaping the barrier coating.
  • the disposable wipe may be used to treat an item, such as a utensil, in order to apply the coating composition to the utensil.
  • the coating composition comprises a carbohydrate gum (C), a humectant (H), and an antimicrobial agent (A), and the coating composition meets the following requirements:
  • the barrier coating layer has antimicrobial cidal or static activity.
  • the coating composition meets the following requirements: about 0.01% ⁇ C ⁇ about 0.4%;
  • the coating composition meets the following requirements:
  • H is a humectant and A is an antimicrobial.
  • the concentration of the humectant may range about 3% to about 8%, 0.35% to less than 1%, or about 0.1% to less than 0.5%.
  • the humectant of the coating composition meets the following requirements: about 0.07% ⁇ H ⁇ 1%. This low-humectant embodiment reduces the stickiness or adhesiveness of the composition to provide a better tactile sensation to the inanimate surface.
  • the coating composition is essentially free of carbohydrate gum, such as for example including less than 0.00009% carbohydrate gum, no detectable carbohydrate gum, or no carbohydrate gum.
  • the term essentially free also include completely free.
  • the coating composition may comprise about 50% to about 98% by weight water, such as, for example, about 75% to about 97% water, or about 85% to about 95% water.
  • the coating composition includes glycerin or one or more similar humectant substances.
  • Humectants similar to glycerin may be classified generally as polyols.
  • the humectants may be, for example, glycerin, sorbitol, xylitol, propylene glycol, polyethylene glycol, and mixtures thereof.
  • an antimicrobial agent is present in the composition.
  • the composition may include one or more anti-viral agents, or antifungals, or antibacterials or a combination thereof.
  • the effect of such antimicrobials includes static and/or cidal activity.
  • the antimicrobial acts by binding to cell membranes of the microorganisms and disrupting them, thereby causing cell death.
  • the coating composition is a broad spectrum antimicrobial, such as an antimicrobial classified as an antiseptic, or possesses activity against viruses, bacteria, and fungi.
  • the antimicrobial agent may include, but is not limited to cationic antimicrobial agents and pharmaceutically acceptable salts thereof, including, for example, monoquaternary ammonium compounds (QAC, cetrimide, benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, myristalkonium chloride, Polycide), biquaternaries and bis- biguanides (Chlorhexidine, Barquat, hibitane), and biguanides, polymeric biguanides, polyhexamethylene biguanides, Vantocil, Cosmocil, diamidines, halogen-releasing agents including chlorine- and iodine-based compounds, silver and antimicrobial compounds of silver, peracetic acid (PAA), silver sulfadiazine, phenols, bisphenols, hydrogen peroxide
  • PAA
  • the antimicrobial may also be or include: antibacterial agents, both cidal and static, and different classes, for example tetracycline, chloramphenicol, fusidic acid, fluoroquinolone, macrolide antibacterial agents, oxazolidinones, quinolone- and
  • the antimicrobial may also include, for example: antifungal agents in the following classes: azoles, polyenes, echinocandins, and pyrimidines. Combinations of the any of the foregoing antimicrobial agents are also contemplated. Many of the foregoing are cationic species or their pharmaceutically acceptable salts, and in an embodiment, cationic antimicrobials are utilized in the composition.
  • the composition is exclusive agents that release gas fumes, such as, for example, chlorine dioxide, or chlorine dioxide producing reactants.
  • the coating composition does not induce mutations or the development of resistance by microbes. This is because of the mechanism of action against the microorganisms by the coating and the selected antimicrobial.
  • the antimicrobial may be present, for example, in an amount ranging from about 0.0005% to 5% by weight of the total composition, such as, for example, about 0.0025% to about 1%, about 0.005 to about 0.006%, or about 0.0006% to about 0.003%. In another embodiment, the antimicrobial may be present, for example, in an amount ranging from about 0.05% to about 0.1% by weight of the total composition, such as, for example, about 0.05% to about 0.06% or about 0.06% to about 0.1%. In an embodiment, the antimicrobial is about 5% or less, or about 3% or less, or about 1.5% or less, such as when the antimicrobial used does not cause solubility problems at higher concentrations.
  • the coating composition used in a method of treating an inanimate surface includes 0.0005% to 5% by weight of a monoquaternary ammonium compound or a pharmaceutically acceptable salt thereof.
  • the coating composition may consist essentially of the monoquaternary ammonium compound or a pharmaceutically acceptable salt thereof.
  • the composition consists essentially of only the humectant and the antimicrobial, such as, additionally including only preservatives, scenting agents, or other agents, that do not affect the trapping or antimicrobial activity of the composition.
  • Consists essentially of or “consisting essentially of as used herein has the meaning that is typically applied, that is, it means, the specified materials and those that do not materially affect the basic and novel characteristic(s) of the composition.
  • the composition may further include components, such as, for example, copovidone and other lubricating agents, parabens such as methyl paraben or propylparaben, scenting agents, preservatives, such as sodium benzoate, buffering agents, such as monosodium and disodium phosphate, sweeteners, hydrogenated castor oil with ethylene oxide, and carboxymethylcellulose.
  • components such as, for example, copovidone and other lubricating agents, parabens such as methyl paraben or propylparaben, scenting agents, preservatives, such as sodium benzoate, buffering agents, such as monosodium and disodium phosphate, sweeteners, hydrogenated castor oil with ethylene oxide, and carboxymethylcellulose.
  • these components may, for example, be included in amounts ranging from about 0.01% to about 5% by weight of the total composition, such as, for example, about 0.1% to about 2%. In another embodiment, the components are included, for example, in amounts of about
  • Buffering agents such as monosodium or disodium phosphate may also be used.
  • the coating composition is a free- flowing liquid suitable for spraying. This is in contrast to a paste or toothpaste composition, which is typically not free-flowing and not suitable for spraying.
  • the coating composition is free of abrasives that are commonly used in toothpaste compositions.
  • substantially free-flowing and substantially free of clumps is judged by passing the composition through a 140 U.S. mesh (0.10 mm pore size), and 95 to 100% of the composition, such as 96% to 99.9% passes through, after 30 seconds.
  • the composition consists essentially of only the gum, the humectant, and the antimicrobial, such as, for example including only additional preservatives, scenting agents, or other agents that do not materially affect the antimicrobial activity.
  • the composition is exclusive of agents for acting against the teeth and/or gums, including, for example, abrasives (such as those used in toothpastes) teeth whitening or desensitizing agents.
  • the composition is exclusive of cellooligosaccharides.
  • the antimicrobial agent is exclusive of lipids such as fatty acid ethers or esters of polyhydric alcohols or alkoxylated derivatives thereof.
  • the composition is exclusive of one or more of time-release agents, allergy-relief compounds, azelastine, silicon based oils, essential oils, polyvinyl pyrrolidone, polyvinyl alcohol, and potassium nitrate.
  • the composition is free of volatile organic compounds, including for example, volatile alcohols.
  • the composition is free of surfactant or foaming agent.
  • the coating composition is non-flammable.
  • a method for making a coating composition includes mixing and heating the antimicrobial agent with other components, such as the humectant and carbohydrate gum. In an embodiment, heating is replaced with extended mixing times. Other components may also be mixed in a single or multiple mixing steps. All components of the coating composition may be mixed at one time to produce a composition with a stable shelf life, such as, for example, being stable for over about 6 months, such as stable for about 1 year to about 3 years, or about 1.3 to about 2 years. This is in contrast to compositions that have active components that must be added separately a short time prior to use, or those that will separate out of solution.
  • the coating composition is a stable one-part composition that does not require mixing with a second composition to activate it for use.
  • the coating composition is in a single phase and is not an emulsion.
  • the composition is a free-flowing liquid and is non-foaming.
  • microorganisms and an antimicrobial agent provides a long-lasting effect, characterized by both in vitro, simulated in vivo, and in vivo examples below.
  • the coating composition was shown to have antimicrobial effect (cidal or static) for at least 6 hours.
  • in vitro tests indicate the antimicrobial effect had a significantly extended duration past about 2 hours, past about 6 hours, and depending on the microorganism tested, such as greater than about 8 hours, about 6 to about 16 hours, and about 24 hours, or more.
  • Post antimicrobial effect is defined as suppression of microbial growth that persists after limited exposure to an antimicrobial agent. Having a longer PAE is considered advantageous for antimicrobial agents as it allows for persistent inhibition of microbial growth, and may affect dosing regimens as agents with long PAEs may need less frequent administration than those with short PAEs.
  • the PAE of the composition when applied to a mucosa has a PAE that persists for about 6 hours or more, such as about 6 hours to about 16 hours, or about 16 hours to about 24 hours.
  • the composition is suitable for spraying, and thus also has a viscosity that is suitable for spraying.
  • the composition has a viscosity of less than 500 cps such as, for example, about 490 cps to about 10 cps, or about 400 cps to about 15 cps.
  • the composition has a viscosity of about 16 to about 20 cps, such as, for example, about 17 to about 19 cps.
  • the coating composition is not hydrophilic which allows the composition to have a greater affinity to adhere to and cover certain surfaces. Furthermore, in an embodiment, the antimicrobial being embedded in the non-hydrophilic composition will allow for sustained antimicrobial activity on treated surfaces. In an embodiment the coating composition is amphiphilic or has amphiphilic components.
  • composition has an Rf value in water of 0 to about 0.25, such as about 0.0001 to about 0.15, or about 0.03 to about 0.1.
  • the composition has a pH of about 4 to about 8, such as about 5 to about 7, or about 6 to about 7.5. In another embodiment the composition has a pH of greater than 5.5 to about 8, wherein antimicrobials such as cetylpyridinium chloride are most effective.
  • fibroblasts Normal human gingival cells (epithelial cells and fibroblasts) were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). The fibroblasts were cultured in Dulbecco's modified Eagle's medium (DME, Invitrogen Life Technologies, Burlington, ON, Canada) supplemented with fetal bovine serum (FBS, Gibco, Burlington, ON, Canada) to a final concentration of 10%.
  • DME Dulbecco's modified Eagle's medium
  • FBS Gibco, Burlington, ON, Canada
  • the epithelial cells were cultured in Dulbecco's modified Eagle's (DME)— Ham's F12 (3 : 1) (DMEH) with 5 ⁇ g/mL of human transferrin, 2 nM 3,3',5' of tri- iodo-L -thyronine.
  • DME Dulbecco's modified Eagle's
  • EDTA ethylenediaminetetra acetic acid
  • the EHOM model was produced by using the gingival fibroblasts and epithelial cells of Example 1 that were used to form a complex three-dimensional spatial cellular organization similar to that found in normal human oral mucosa.
  • the lamina basement membrane was produced by mixing Type I collagen (Gibco-Invitrogen, Burlington, ON, Canada) with gingival fibroblasts, followed by culture in 10% FBS-supplemented medium for four days. The lamina intestinal was then seeded with gingival epithelial cells to obtain the EHOM.
  • the tissue specimens were grown under submerged conditions until the total surface of the lamina intestinal was covered with epithelial cells.
  • the EHOM was raised to an air-liquid interface for four more days to facilitate the organization of the epithelium into its different strata.
  • the lamina basement membrane is a thin layer of loose connective tissue that lies beneath the epithelium and together with the epithelium constitutes the mucosa.
  • Figure 2 shows an illustration of the EHOM mucosal tissue, with an arrow pointing to its location in a schema depicting mucosa covered with the coating composition.
  • compositions were created by adding the ingredients listed below in a 50-mL centrifuge tube, and vortexing to bring to "free-flow" consistency.
  • the constituents of the compositions and their approximate amounts are given in Table I (the values in Table I are percentages by weight of the total composition):
  • Example 27 EHOMs of Example 2 were put in contact with 1 and 5% dilutions (diluted in serum free culture medium) of Example 4 for 2 minutes. Tissues were then washed twice with serum free culture medium then over layered with lxlO 6 Candida microbial cells in a volume of 300 ⁇ . Tissues were then put on air-liquid culture plates and incubated for 24 hours in 5% CO 2 humid atmosphere at 37°C. Next, the culture medium underneath the EHOM (ventral chamber) was collected and seeded on Sabouraud agar plate to verify whether or not the microorganisms penetrated through the tissue and reached the culture medium below. A culture was also obtained from the EHOM surface and seeded on Sabouraud agar plate. The process is graphically depicted in Figure 3.
  • Example 28 EHOMs of Example 2 that were treated with 1 and 5% dilutions of the Example 4 composition for 2 minutes were over layered with Candida microbial cells for 24 hours were flipped onto Sabouraud dextrose agar plates and left in place for 5 minutes. The EHOMs were then removed and the plates were incubated for 24 hours at 30°C, after which microbial growth was ascertained macroscopically and photographed. Each experiment was repeated 5 independent times with similar results.
  • Figure 4 shows the results of the cultures of the EHOM surface (panels C and D) and the culture of the pass-through liquid from the bottom (ventral) chamber (panels A and B).
  • Example 4 composition forms a barrier coating that prevents passage of microbes through the EHOM tissues but does not have an inherent anti-microbial effect.
  • Example 29 and 30 were repeated, except the EHOM were infected with X mutans. Similar results were obtained that indicated that the coating compositions formed a barrier coating preventing the S. mutans microbes from passing through the barrier coating, but did not have an antimicrobial effect.
  • Example 32 a set of EHOM tissues from Example 2 was treated with the coating composition of Example 4 and then overlaid with C. albicans. In control Example 31 a control set was not treated with the coating composition prior to overlayering with C.
  • Figure 5 shows the effect of the coating composition on microbial invasion of EHOM tissues.
  • Panel (A) is a representative photograph of the untreated control Example 31, and panel (B) is a photograph of the treated Example 32.
  • the arrow indicates invading fungal hyphae in the untreated control Example 31.
  • the EHOM model described above was also used to evaluate the ability of Examples 5-7 to form a barrier coating that: (a) prevents oral bacteria (S. mutans) and fungi (Candida albicans) from penetrating/invading human oral mucosa, and (b) does not cause damage to host cells (cytotoxicity assay).
  • Examples 33-40 after pre-treatment and incubation according to the procedures of Examples 27 and 28: (1) the flow-through medium was collected from the lower chamber; and (2) tissues were flipped and placed onto the surface of Sabouraud dextrose agar Petri dishes, and incubated for 24 hours. Collected flow-through media were spread onto agar media plates, and incubated for 24 hours also as described in Examples 27 and 28. Table II also indicates the figure in which a photo of each Example was taken showing the microbial growth on each flipped Example culture.
  • Figures 6 and 7 show that both Candida and Streptococcus were able to grow on the surface of EHOM treated with the compositions of Examples 5-6.
  • no microbial growth was observed when the "flow-through" medium collected from the lower chambers of EHOMs of Examples 36 or 40, i.e. those treated with the Example 7 composition.
  • Similar results were obtained with EHOM treated with the compositions of Examples 5 and 6 (data not shown). These data indicate that the combination of glycerine and xanthan gum is capable of forming a protective barrier coating on mucosal tissues.
  • Tested Formulations are not Toxic and do not Cause Damage to the Cells/Tissues
  • the EHOM model was used to assess the toxicity of the composition. Examples 41-47 were formulated as stated in Table III. Table III
  • Examples 41-48 irrespective of whether the formulations contained cetylpyridinium chloride with or without preservatives and infected with either Candida albicans or S. mutans, respectively. These data confirmed the non-toxic effect of the Example coating compositions and that these formulations maintained the integrity of the host mucosal tissues.
  • compositions represent an effective and a safe barrier that can prevent microorganisms from penetrating and invading human mucosal tissues.
  • Example 7 coating composition was evaluated against many bacteria and yeasts.
  • the antimicrobial activities of the Example 7 coating composition were evaluated against a number of clinical isolates obtained from patients, including S. salivarius, P. gingivalis, S. pyogenes, S. pneumonia, Fusobacterium nucleatum, S. mutans, S. aureus, Y. enterocolitica, S. oralis, S. mitis, C. albicans, C. krusei, C. tropicalis, and C. glabrata.
  • Activity of the Example 7 coating composition was evaluated by determining its minimum inhibitory concentration (MIC) using reference methods described in the Clinical and Laboratory Standards Institute (CLSI) documents M07-A8, M11-A7, and M27-A3.
  • CLSI Clinical and Laboratory Standards Institute
  • Example 7 containing 0.1 % CPC, or 1 ⁇ g/ml
  • CHX chlorhexidine gluconate
  • the coating composition was also found to have potent antimicrobial activity against: MRSA, Acinetobacter baumannii, Streptococcus sanguis, S. gordonii, and Aggregatibacter actinomycetemcomitans.
  • Example 7 composition exhibited potent activity against many aerobic and anaerobic bacteria, as well as the fungi.
  • the MIC of the Example 7 coating composition against S. oralis and S. mitis was noticeably elevated (500 ⁇ g/mL) compared to other organisms. It is interesting to note that S. oralis and S. mitis are normal commensals of the oral cavity. Activity of the commonly used antimicrobial chlorhexidine (2% solution) was also determined by the same method. Table IV shows the MIC of the Example 7 coating composition and chlorhexidine (2% solution) as a comparative example against various microorganisms.
  • Example 7 possesses potent activity against pathogenic bacteria and fungi commonly isolated from the oral cavity. This activity was more potent than that observed for chlorhexidine.
  • mutans has an MIC of 5.0 - 6.25 ⁇ g/mL, which is much less effective than the 1.95 ⁇ g/mL reported in Example 53. This was an unexpected result since CPC has the risk of losing its activity when mixed with other excipient chemicals in a formulation. See
  • Example 8 The PAE of Example 8 against several microorganisms was evaluated in Examples 63-68.
  • Control Example 69 was also provided. Several microorganisms were exposed to Example 8 (at a concentration equal to the MIC) for 1 min followed by three washes to remove residual formulation. The treated cells were then spread on agar medium plates, which were incubated at 37 °C, and the time taken for the cells to re grow was determined. PAE was expressed as the time (in hours) for which growth inhibition (%) was maintained by the Examples 63-68, compared to the untreated control Example 69.
  • Example 8 exhibited a PAE ranging between 4 hours to 24 hours, depending on the organism tested (S. aureus, S. pneumonia, S. gordonii, S. sanguis, S. salivarius, and S. mitis). Similar activity of Example 8 was observed against Candida (data not shown). Other Example coating compositions exhibited similar PAE against
  • Example 7 exhibits greater prolonged antimicrobial activity than comparative Example 70, and that additional amounts of CPC have more than a simple additive effect on anti-microbial activity.
  • Examples 71-73 cells were grown in the presence of Example 3 for 24 hours. Next, the cells were washed to remove residual formulation, dehydrated by passing through a series of alcohol solutions (10% to 100%, v/v) and processed for SEM analysis. Control Examples 74-76 differed from Examples 71-73 in that they were not grown in the presence of Example 3.
  • Example 3 1 : 1 dilution with appropriate medium.
  • biofilms were scraped, spread on culture media, incubated and colony forming units (CFUs) were determined.
  • Media diluted with phosphate buffered saline (PBS, 1 : 1) were used as a control. Table V reports data at 0 (Control), 15, 30, and 60 minutes.
  • Figure 12 also reports data on Examples 77-79 as a graph of % inhibition versus growth control. These results showed that Example 3 coating composition inhibited bacterial and fungal microbes with an MIC of 0.2% against biofilms formed by S. salivarius, S. oralis, or C. albicans.
  • Example 80 we evaluated the effect of 1 minute exposure of C. albicans early phase biofilms to Example 3, and found that even with an exposure for as short a time as 1 minute, it was able to inhibit biofilm formation (Figure 13).
  • Example 81 was an untreated control sample.
  • Example 7 possesses potent activity against biofilms formed by bacteria and fungi.
  • the Coating Composition is also Active against Viruses
  • the coating composition inhibits the infectivity of influenza A
  • MDCK Madin Darby canine kidney
  • Example 85 cell monolayers were exposed to the Example 7 coating composition.
  • control Example 86 the cell layers were exposed to optiMEM (+P/S,+Lglu) tissue culture media for different times: (1) Tl : 30 min exposure, (2) T2: lh exposure, (3) T3 : 2h exposure.
  • MOI multiplicity of infection
  • TO infected immediately after exposure
  • Infected cells were then centrifuged, resuspended in 500 ⁇ of growth medium, and incubated at 32.5 °C for 48 hours.
  • Immunofluorescence microscopy (using FITC labeled anti-influenza antibody) was also used to evaluate the effect of the Example 7 coating composition on the ability of influenza virus to infect mammalian cells.
  • Figure 14 shows the effect of Example 7 on cytopathic effects of influenza-infected MDCK cells (Example 85) (panels A and C), and control Example 86 (panels B and D). Images were obtained from: phase contrast (A-B), and immunofluorescence microscopy (C- D). No identifying cytopathic effect (CPE) was observed in formulation-treated cells.
  • Untreated cells displayed typical CPE including focal rounding and degenerative changes.
  • Example 85 The data showed that exposure of cell monolayers to Example 7 for 30 minutes, 1 hour, or 2 hours remained confluent and healthy (Example 85). In contrast, in the untreated cells and cells treated immediately prior to infection (TO) (control Example 86) demonstrated substantial cytopathic effect. As seen in Figure 14 panel C, no fluorescence was observed in the coating composition treated cells of Example 85, while the untreated cells of Example 86 exhibited fluorescence ( Figure 14 panel D).
  • Figure 16 shows levels of influenza virus in infected treated cells (Example 87) and untreated cells (Example 88), as determined by quantitative PCR.
  • Example 87 cells were treated with Example 7 and in control Example 88 the cells were left untreated. Later the supernatants were collected and analyzed for the presence of virus.
  • a reference standard was prepared using a cDNA fragment of the H1N1 matrix gene and human RNAse P amplified by conventional RT-PCR, gel purified (QIAquick, Qiagen, Valencia, CA), and quantified using a spectrophotometer (Beckman Coulter, Brea, CA).
  • Example 87 cells treated Example 7 for 30 min or 60 min did not have detectable influenza at 48 hours post infection. Moreover, treatment with Example 7 for 2 hours resulted in a 6-fold decrease in viral load, compared to the untreated control or those treated immediately prior to infection (Example 88).
  • Coating Composition has Direct Antiviral Effect Against Influenza Virus
  • Example 89-91 a standardized amount of influenza (0.1 MOI) was pretreated for 5 minutes at room temperature with: (1) Example 7 (to form Example 89), (2) control Example 6, a compound without CPC but with preservatives (to form Example 90), and (3) control Example 5 placebo alone (a compound without CPC and preservatives) (to form Example 91). After the 5 minute incubation virus/drug mix was diluted by an additional equal volume with optiMEM (+P/S,+Lglu) to dilute out the treatment compositions.
  • optiMEM (+P/S,+Lglu
  • Example 89-91 CV-1 cells were prepared as described in above. The Example 89-91 treated and untreated viruses were then inoculated onto the cells as described above.
  • Influenza viral load was determined by real time PCR as described above.
  • the data as shown in Figure 17 showed significant decrease in viral load for influenza virus pretreated with the Example 7 coating composition containing the antimicrobial agent CPC (Example 89), compared to those containing only the coating composition and/or preservative but no CPC (Examples 90 and 91).
  • Pre-treatment of virus with Example 7 exhibited significant decrease in viral copies, compared to formulations with no CPC.
  • Example 7 coating composition possesses direct antiviral activity against influenza virus that is not inherent in Examples 5 and 6.
  • Example 7 African Green Monkey Kidney (CV-1) cells were grown in 24-well plates to 90% confluence. Next, the coating composition, Example 7, was applied to the cells (20% Example 7, 80%OptiMeM, working CPC concentration of 0.02 %.) in Example 92. Each time point matched with control Example 93 (No coating composition applied, 100% OptiMeM). The coating composition was allowed to dwell on the surface for 30 minutes, and then removed from the ceil monolayer. Cells were thoroughly washed twice with sterile optiMEM (+PfS,+Lglu).
  • Figure IB may be referred to as a possible mechanism accounting for the inhibition of infection.
  • Examples 94-96 determined whether the coating composition possessed activity against HIV. Host MT mammalian cells were plated into 96-well round bottom plates at a density of 15,000 cells/well in RPMI/10%FBS/PS. The next day (Day 2), virus was pretreated with control Example 5 (to form Example 94), control Example 6 (to form
  • Example 95 or Example 7 (to form Example 96) for 5 minutes and added to cells.
  • the MT (macaque) mammalian cells were washed 3 times with phosphate buffered saline (PBS) and fresh media was replaced.
  • Supernatant (10 ⁇ ) was collected post-treatment on Days 1, 2, 5, 6, 7, and 9, and the viral load was determined by reverse transcriptase (RT) activity.
  • Figure 19 shows a graph of the viral copies per mL for each of Examples 72-74 over a 9 day span.
  • Example 7 in Example 96 exhibited anti-HIV activity at all time points monitored post-treatment.
  • Example 97 An experiment was performed to determine whether the coating composition exhibits activity against the common oral Epstein-Barr virus (EBV). Western blotting was used to evaluate the ability of the Example 8 coating composition to degrade lytic viral protein EAD (indicating inhibition of viral replication).
  • EBV Epstein-Barr virus
  • Example 97 EBV-infected gastric epithelial cells were exposed to different dilutions (1 : 16, 1 :32 and 1 :64) of Example 8, and the presence of EAD protein was detected using specific antibodies. Presence of cellular ⁇ -actin was used as an indicator of epithelial cell integrity. As shown in Figure 20, 1 :64 dilution of Example 8 degraded EAD without affecting cellular actin. These results demonstrate that Example 8 specifically inhibits viral replication, and as such, is an effective anti-viral and useful for prevention of viral infection.
  • Example 98 In control Example 98 an untreated EHOM was tested. In Example 99 S. mitis bacteria was overlaid on the coating composition as described above.
  • Example 100 is a comparative example showing the activity of commercially available LISTERINE
  • Example 101-103 the same procedure of Examples 98-100 was performed except Candida albicans fungus was tested on the coating composition as described above. Table IX shows the results.
  • Example 103 is comparative, showing the activity of commercially available LISTERINE.
  • Example 7 coating composition maintained activity for up to and including 24 hours.
  • these results showed that unlike LISTERINE, the Example 7 coating composition continued to maintain an intact barrier on EHOM tissues for up to and including 24 hours.
  • Examples 104-153 were performed to identify further examples of concentrations of glycerin and xanthan gum that can form a barrier effective in preventing the passage of microorganisms. Since this application does not require a barrier that prevents passage of microorganisms, this data is omitted. However, patent publication U.S. 2012/0270909 as well as the provisional applications that this application claims the benefit of priority to, include this information.
  • an effective barrier coating for a surface treatment may be formed at lower concentrations of glycerine and/or xanthan gum when an effective antimicrobial is added. This is because the antimicrobial and barrier coating act in tandem to stop and/or kill the harmful microbes. In the case of a composition for applying to an inanimate surface, it is not so important to block passage of a microorganism to the other side of the barrier coating, since an inanimate surface cannot be infected.
  • Glycerine-Xanthan Gum Formulations Form a Coating on the Human Oral Mucosa
  • Example 7 formulation with Gentian Violet (GV) as a marker dye.
  • the spiked product 750 ⁇ was sprayed onto the oral cavity of human volunteers. Post-application, the oral cavity was inspected for staining, and the images were captured using a digital camera. As shown in Figure 21, the formulation stained both cheeks and the dorsal/ventral surface of the tongue.
  • Example 162 S. mutans microbial cells were exposed to Example 7 for one minute, washed to remove any residual agent, and allowed to grow in a petri-dish containing fresh growth medium. Growth of organisms at 37 °C was monitored for a 6 hour period, and photomicrographs were taken every 20 minutes over the 6 hour incubation period using a camera connected to the microscope.
  • Example 7 The duration of activity of Example 7 was determined in healthy individuals by evaluating the effect of a single application on microbial burden of the oral cavity.
  • three healthy individuals (over 18 years of age, healthy mouth) were enrolled with informed consent, and asked to apply a single application of the composition of Example 7 on their cheeks.
  • a single application was defined as three sprays of 0.25 ml each in volume.
  • swabs were collected from these individuals at baseline (pre-treatment), 1 hour, 2 hours, and 6 hours post-treatment. Swabs were cultured on agar media plates specific for aerobic or anaerobic organisms, incubated for 24-28 hours at 37 °C, and the number of CFUs were counted. Effect of Example 7 on microbial burden was determined (CFUs), and percentage inhibition was calculated for each post-exposure time point relative to the baseline (0 minutes) CFUs.
  • Example 7 led to consistent reduction in microbial load for up to 6 hours (See Figure 23 A, which shows CFUs of a representative tested individual. Treatment with the coating composition resulted in 69% to 96% reduction of the microbial burden in the oral cavity (See Figure 23B, which shows a representative individual's reduction in microbial load.)
  • Example 167-169 The activity of the coating composition over a 5-day period against oral microbes was evaluated.
  • Example 167-169 three healthy individuals were enrolled, and asked to apply a single dosage (three sprays 0.75 mLs total) of Example 7 three times daily (approximately 9 AM, noon, and 3 PM) for a 5-day period (representing a typical 5-day work-week).
  • Swabs were collected from these individuals at baseline (before application on day 1) and at the end of the day on each day during the 5-day period. Collected swabs were cultured on agar media plates, incubated for 24-28 hours at 37 °C and at 5% CO 2 humidity, and the number of CFUs were counted.
  • Example 7 coating composition The effect of the Example 7 coating composition on microbial burden was determined (as median CFUs for the three subjects), and percentage inhibition was calculated for each post-exposure time point relative to the baseline (0 min) CFUs.
  • Figure 24 shows these results in a graph of CFUs versus time ( Figure 24A) and reduction in microbial load versus time ( Figure 24B).
  • Examples 167-169 demonstrate that application of Example 7 over 5 days led to consistent reduction in microbial load over the 5-day test period ( Figure 24A).
  • Treatment with the Example 7 coating composition resulted in 65% -88% reduction of the median microbial burden in the oral cavity of the study participants ( Figure 24B).
  • One group used the example coating composition every two hours, three times a day, for five days (a typical work week).
  • the other group used the example coating composition every two hours, four times a day, for five days (a typical work week). No substantial difference was noted in the two groups.
  • Swabs were collected on days 1, 2, 3, and 5 at the end of the day (8 hours after the first administration of the coating composition) and cultured on media specific for aerobic and anaerobic bacteria. Data were presented as number of microbes: total, aerobic and anaerobic.
  • Figure 25 shows a graph of total microbial load and breaks down the total into aerobic and anaerobic counts from just prior to treatment and on day 5 of treatment.
  • Figure 26 shows graphs of microbial load over the 5 day period in oral samples obtained from three representative study participants.
  • the in vivo testing showed that the coating composition exhibits antimicrobial activity against oral microbes, as measured by reduction in the levels of these organisms, over both short- and long-term duration.
  • the data showed that treatment with the coating composition over a 5-day period resulted in reduction in the oral microbial load, for total microbes, aerobic and anaerobic organisms.
  • Example 199 an in vitro filter insert-based model (see Figure 27) was used to test different humectants at different concentrations.
  • Example 199-205 were placed into filter inserts (pore size 0.8 ⁇ diameter, that allows both bacteria and fungi to pass through) and allowed to form a layer.
  • organisms were overlaid on the layer formed by the test solutions.
  • the filter inserts containing the layer of test solutions and microorganisms were then placed on the surface of agar media plates and incubated for 24 hours at 37 °C. After the incubation period, the agar media plates were evaluated for growth on filter insert and in the agar media. Growth on filter insert but no growth in agar media indicated that the test solution formed a barrier, which prevented the microbes from passing through. In contrast, microbial growth in the filter insert as well as the agar media indicated that no such barrier was formed.
  • Example 214 the formulation of Example 7 was made, except the neutral agent Citral was used instead of CPC.
  • the assay described above in Examples 48-61 was used to perform these studies.
  • Example 215 thin layer chromatography analysis was used to compare the hydrophobicity of Example 7 with a hydrophobic composition.
  • composition was comprised of the components in Table XII.
  • Example 7 10 ⁇ of Example 7 and the hydrophobic composition were deposited on pre-made TLC plates (at a distance of 2 cm from the bottom edge). The spots were air-dried for 5 minutes, and the plates were placed in a TLC chromatography jar containing water as a solvent. The TLC system was allowed to run until the solvent front reached the top edge of the plate. Plates were removed and the solvent and sample fronts were marked. The Relative Front (Rf) values were calculated for the two samples using the formula I:
  • a coating composition was made by mixing the components according to Table XIII below in water to form a solution.
  • a eucalyptol component was also included in an amount of 5X per the Homeopathic Pharmacopeia, but also did not affect the test results, other than demonstrating that the composition still works with this component added into it. All percentages are by weight.
  • the coating composition was also shown to have effectiveness in killing allergy causing molds. MIC tests were performed on a polystyrene plastic surface.
  • Example 217 the coating composition of Example 216 was tested to determine its
  • Example 7 had an MIC of 0.06 micrograms/ml.
  • Example 218 the coating composition of Example 216 was tested to determine its MIC against Aspergillus fumigatus 18748.
  • the Example 7 composition had an MIC of 0.49 micrograms/ml.
  • Example 219 the coating composition of Example 216 was tested to determine its MIC against Cladosporium.
  • the Example 7 composition had an MIC of 0.39
  • Example 219-221 three silicone elastomer discs with a 1 cm diameter were pre- sprayed with .25 mL with the Example 7 coating composition for 60 min and incubated at 37 °C.
  • Example 222-224 a control example was performed by treating a silicone elastomer disc with an equivalent amount of a phosphate-buffered saline (PBS) for 60 minutes and incubated at 37 °C.
  • PBS phosphate-buffered saline
  • Example 219-224 pretreated discs were each submerged in 4 mL MRSA suspension (l x lO 7 cells/mL), and incubated at 37 °C for 90 min ("Adhesion Phase"). Next, the discs with adherent cells were removed and transferred to wells containing 4 mL of Brain Heart Infusion (BHI). The wells were incubated at 37 °C on a rocker for 24 hours. Biofilm formation on the discs was evaluated by quantitative culturing on BHI agar plates. Scanned images of the wells were recorded using a scanner.
  • BHI Brain Heart Infusion
  • FIG. 28 shows images of colony burden in biofilms formed by MRSA on the PBS treated (A, C, E) and Example 7 treated (B, D, F) discs.
  • Example 7 coating composition was tested to determine its efficacy against several strains of Bordetella pertussis.
  • test Examples 225-235 agar-based assays were constructed in which Example 7 coating composition was incorporated in Regan-Lowe Charcoal agar BBL #297883 plates as a 64 microgram/mL dilution in water.
  • Control Examples 236-246 were agar plates containing no Example 7 coating composition.
  • 5xl0 4 cells (50 uL) of Bordetella pertussis were spotted on the test surface and plates were incubated at 37 degrees C for 24 hours.
  • Table XV confluent growth was observed in control Examples 236 to 246, while no growth was observed in test Examples 236-246.
  • the designation 4+ means luxurious growth.
  • Example 7 The antiviral activity of the coating composition, Example 7 (in various diluted concentrations) was evaluated against the ATCC VR-1200 strain of rhino virus.
  • DMEM Dulbecco's Modified Eagle Medium
  • Lglu L-glutamine
  • P/S penicillin/streptomycin
  • Example 7 composition was applied to cell monolayers at varying concentrations (5%, 10%, 15%, 20%, 50% diluted in 400 microliter optiMEM (+P/S, +Lglu)) for a working CPC concentration of 0.005%, 0.01%, 0.015%, 0.02% and 0.05% respectively, and was allowed to dwell for 1 hour prior to inoculation.
  • 400 microliter optiMEM (+P/S,+Lglu) was applied to the cells and allowed to dwell for 1 hour prior to inoculation.
  • the cell monolayers were then removed from the Example 7 dilutions or control optiMEM and rhinovirus was applied at a multiplicity of infection (MOI) of 0.1.
  • MOI multiplicity of infection
  • Rhinovirus viral titer of the Example 247-251 cell culture supernatants were measured by real time PCR. In comparison to Control Example 252 significantly decreased rhinovirus viral load was demonstrated in Example 251, which was a 50% concentration of Example 7.
  • a test Example 253 was formulated with a 50% Example 7 diluted suspension (0.05 CPC concentration) in 500 microliter optiMEM (+P/S,+Lglu).
  • a control Example 254 was formulated as a control solution with no Example 7 (500 microliter optiMEM (+P/S,+Lglu)). Examples 253 and 254 were applied the cells disclosed in Examples 246-252, but at defined intervals: T-l hour, T-30 min, and T-0 (Immediate) prior to infection.
  • the cell monolayers were then removed from the Example 253 suspension and the Example 254 control solution.
  • the rhinovirus viral particles were applied to the treated cell monolayers at a multiplicity of infection (MOI) of 0.1.
  • MOI multiplicity of infection
  • Cells were incubated with virus at 32.5°C for 1 hour. After which the inoculum was removed and 500ul OptiMEM +P/S +Lglu was placed on the cells.
  • Cells were then grown at 32.5°C at 5% CO 2 for 5 days.
  • the cells treated with Example 253 and 254 were viewed daily for the presence of cytopathic effect. After 5 days incubation, cell culture supernatant was gathered for immunofluorescence and rhinovirus viral load quantification.
  • Figure 29 discloses photos of cells treated with test Example 253 at Figure 29(a) T - 1 hr, Figure 29(c) T - 30 min and Figure 29(b) T 0 (immediate). None of these photos demonstrated any cytopathic effect and healthy cells overgrew the plate. However, as shown in Figure 29(d) the Example 254 untreated control cells demonstrated focal rounding, detachment and cell death. Cytopathic effect determination included the development of focal rounding, cell size enlargement or reduction, syncytial formation, development of multinucleated giant cells, and detachment.
  • Immunofluorescence was determined as follows: Virus infected cell monolayers and uninfected control were washed with sterile PBS. The cells were trypsinized, spotted upon wells on slides and fixed with acetone. The slides were tested by DFA employing FITC labeled monoclonal antibodies. An indirect immunofluorescence assay was performed using Light Diagnostics Pan-Entero virus Detection Kit (Millipore). This detection kit is well described for having cross reactivity with rhinovirus infected cells. All antibody dwell steps occurred for 1 hour at 37°C. Following a final wash, cells were evaluated at a wavelength of 488 nm for the presence of fluorescence.
  • Figure 30 discloses immunofluorescence photos of cells pretreated treated with test Example 253 at Figure 30(d) T - lhr, Figure 30(b) T - 30min and Figure 30(c) T-0
  • Viral load for the samples was quantified as follows: Cell culture supernatants were collected and stored at -80°C. Nucleic acid was extracted using QIAamp Viral RNA Kit (QIAGEN, Valencia, CA). Random hexamer primers (Invitrogen Carlsbad, CA) were used to create a cDNA library for each specimen. Reverse transcription reactions were performed with M-MLV RT (Invitrogen, Carlsbad, CA) according to the manufacturer's specifications. Quantitative analysis was performed on a StepOne Plus Taqman Real Time PCR (Applied Biosystems, Branchburg, NJ ) using TaqMan Universal PCR Master Mix (Applied
  • Example 255 a cetylpyridinium chloride-based spray disinfectant was evaluated for its activity against methicillin-resistant Staphylococcus aureus (MRSA). The antibacterial effect of pre-coating surfaces with the composition was analyzed, and the effect of a water rinse on maintaining its activity was also analyzed.
  • MRSA methicillin-resistant Staphylococcus aureus
  • the coating composition containing cetylpyridinium chloride retains a substantial amount of its cidal or static activity even on stainless steel surfaces after washing with water, such as at least about 35%, about 35% to about 50%, or about 15% to about 40% of cidal or static activity after washing with water.
  • test CPC composition had the following formula: 93% to 97% water, 0.5 to 1% CPC antimicrobial, 0.5 to 1% glycerin, with the remainder of the composition comprising preservatives, such as cremophor RH 60, copovidone, parabens, and sodium benzoate, none of which were present in an amount more than about 1%.
  • CPC s a The activity of the test CPC composition (CPC s a) was evaluated by soaking stainless steel carriers with MRSA suspension (1 x 10 8 cells) for 15 min at 37°C. Next, excess fluid was drained, the carriers sprayed with CPC s a (0.5 mL dosages) for 30 seconds, air dried, and incubated in Brain heart infusion medium (BHI) overnight. Aliquots of the medium were then quantitatively cultured.
  • a commercial disinfectant containing benzalkonium chloride and ethanol was used as a comparator (Bkc-EtOH), and was identically tested.
  • the comparator also showed similar antibacterial activity.
  • Example 255 composition is comparable in initial antimicrobial activity it is superior in all safety categories and activity after a water rinse.
  • Table XXIX shows a comparison is made by comparing the composition made in Example 255 (Formulation 2) having no gum and only a low humectant percentage with a composition containing the carbohydrate gum component, such as was described in Example 7 (Formulation 1).
  • Example 261 shown in Figure 34, a glass window pane was cleaned and polished so it was spotless. A 0.25 mL dose of Formulation 1 was centrally applied and then wiped concentrically in an area of approximately 12 inches in height and width. The window was then photographed to analyze whether the formulation left any visible residue (or "streaking") on the glass after being firmly wiped. This test method was repeated for Formulation 2. It was observed that the test Formulation 1 left a noticeable streak or visible residue, whereas the test Formulation 2 was free of any streaking or visible residue.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Plant Pathology (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Paints Or Removers (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé pour piéger et neutraliser ou tuer des micro-organismes sur une surface, qui comprend : l'application d'une composition de revêtement à faible adhérence qui comprend un agent antimicrobien sur une surface inanimée; dans le revêtement, l'extermination ou la neutralisation de micro-organismes rencontrés sur la surface et rencontrés dans l'environnement après l'étape d'application est réalisée; la formation d'une couche de revêtement sur la surface inanimée. La composition comprend un agent humectant et un agent antimicrobien, l'agent antimicrobien comprenant un composé de mono-ammonium quaternaire ou un sel pharmaceutiquement acceptable de celui-ci. La couche de revêtement a une activité bactéricide ou statique antimicrobienne pendant au moins environ une heure. L'invention concerne également une composition antimicrobienne à faible adhérence.
PCT/US2013/066929 2012-11-12 2013-10-25 Composition de revêtement antimicrobienne de surface à faible adhérence et procédé d'application WO2014074331A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261725375P 2012-11-12 2012-11-12
US61/725,375 2012-11-12
US13/734,363 2013-01-04
US13/734,363 US20130123308A1 (en) 2011-04-19 2013-01-04 Long-lasting surface anti-microbial and method of application
US201361829608P 2013-05-31 2013-05-31
US61/829,608 2013-05-31

Publications (1)

Publication Number Publication Date
WO2014074331A1 true WO2014074331A1 (fr) 2014-05-15

Family

ID=50685077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/066929 WO2014074331A1 (fr) 2012-11-12 2013-10-25 Composition de revêtement antimicrobienne de surface à faible adhérence et procédé d'application

Country Status (1)

Country Link
WO (1) WO2014074331A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398645B2 (en) 2011-04-19 2019-09-03 Arms Pharmaceutical, Llc Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
CN110898075A (zh) * 2019-12-27 2020-03-24 温海 聚六亚甲基双胍在抑制、杀灭红色毛癣菌、须癣毛癣菌、犬小孢子菌及白念珠菌中的应用
CN111826304A (zh) * 2020-05-25 2020-10-27 深圳迪健生物科技有限公司 一种嗜热链球菌及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0736250A1 (fr) * 1994-10-21 1996-10-09 Japan Clinic Company Limited Agent antimicrobien contenant du sel d'ammonium quarternaire
WO1999059410A1 (fr) * 1998-05-21 1999-11-25 Troy Technology Corporation, Inc. Compositions antimicrobiennes stabilisees comprenant des composes halopropynyle
WO2007016067A2 (fr) * 2005-07-29 2007-02-08 Delaval, Inc. Composition antibactérienne et procédé d’utilisation
RU2325899C2 (ru) * 2004-01-29 2008-06-10 Дзе Проктер Энд Гэмбл Компани Композиции для ухода за полостью рта, содержащие четвертичные аммониевые антимикробные реагенты с повышенными уровнями биологической доступности

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0736250A1 (fr) * 1994-10-21 1996-10-09 Japan Clinic Company Limited Agent antimicrobien contenant du sel d'ammonium quarternaire
WO1999059410A1 (fr) * 1998-05-21 1999-11-25 Troy Technology Corporation, Inc. Compositions antimicrobiennes stabilisees comprenant des composes halopropynyle
RU2325899C2 (ru) * 2004-01-29 2008-06-10 Дзе Проктер Энд Гэмбл Компани Композиции для ухода за полостью рта, содержащие четвертичные аммониевые антимикробные реагенты с повышенными уровнями биологической доступности
WO2007016067A2 (fr) * 2005-07-29 2007-02-08 Delaval, Inc. Composition antibactérienne et procédé d’utilisation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398645B2 (en) 2011-04-19 2019-09-03 Arms Pharmaceutical, Llc Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
CN110898075A (zh) * 2019-12-27 2020-03-24 温海 聚六亚甲基双胍在抑制、杀灭红色毛癣菌、须癣毛癣菌、犬小孢子菌及白念珠菌中的应用
CN110898075B (zh) * 2019-12-27 2021-08-03 温海 聚六亚甲基双胍在制备抑制和/或杀灭犬小孢子菌的药物中的应用
CN111826304A (zh) * 2020-05-25 2020-10-27 深圳迪健生物科技有限公司 一种嗜热链球菌及其应用

Similar Documents

Publication Publication Date Title
US20150031729A1 (en) Low-tack surface anti-microbial coating composition and method of application
US20130123308A1 (en) Long-lasting surface anti-microbial and method of application
US20190358149A1 (en) Method of inhibiting harmful microorganisms and barrier-forming composition therefor
KR102108109B1 (ko) 국소 소독 제제 및 이의 용도
US20140011766A1 (en) Antimicrobial compositions and methods
JP6579529B2 (ja) 抗菌組成物
US20200093811A1 (en) Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US20130123309A1 (en) Method for reducing microbial load for individuals with elevated risk conditions
BR112014009479B1 (pt) Composição líquida de limpeza pessoal e método de desinfecção da superfície externa
WO2014074331A1 (fr) Composition de revêtement antimicrobienne de surface à faible adhérence et procédé d'application
JP6901824B2 (ja) 微生物により引き起こされる若しくは悪化する疾患の治療方法、又はその症状の緩和方法
EP2838570A1 (fr) Produit antimicrobien de surface de longue durée et procédé d'application
WO2014107572A1 (fr) Composition et procédé de traitement de surface corporelle
US20150306042A1 (en) Body surface treatment composition and method
US20230050626A1 (en) Bladder, ureter, kidney, urethra, prostate and catheter anti-microbial, and biofilm prevention, reduction and treatment
US20230301884A1 (en) Antiseptic compositions
US20240041852A1 (en) Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
EP2941248A1 (fr) Composition et procédé de traitement de surface corporelle
WO2021259215A1 (fr) Compositions antiseptiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13852992

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13852992

Country of ref document: EP

Kind code of ref document: A1